✍️ 🧑‍🦱 💚 Autor:innen verdienen bei uns doppelt. Dank euch haben sie so schon 431.453 € mehr verdient. → Mehr erfahren 💪 📚 🙏

RNA INTERFERENCE IN HUMAN EMBRYONAL CARCINOMA AND EMBRYONIC STEM CELLS

RNA INTERFERENCE IN HUMAN EMBRYONAL CARCINOMA AND EMBRYONIC STEM CELLS

von Maryam M. Matin und Peter W. Andrews
Softcover - 9783838379111
59,00 €
  • Versandkostenfrei
Auf meine Merkliste
  • Hinweis: Print on Demand. Lieferbar in 5 Tagen.
  • Lieferzeit nach Versand: ca. 1-2 Tage
  • inkl. MwSt. & Versandkosten (innerhalb Deutschlands)

Autorenfreundlich Bücher kaufen?!

Beschreibung

Human embryonal carcinoma (hEC) cells are the stem cells of teratocarcinomas. Human embryonic stem (hES) cells are pluripotent cells derived from inner cell mass of human embryos at blastocyst stage, and can be induced to differentiate into all three embryonic germ layers. hES cells offer the opportunity for in vitro production of multiple cell types for use in regenerative medicine. A key to unlocking this potential is development of methods for controlling gene expression and, consequently, cell differentiation. One tool that might be exploited is RNA interference (RNAi) to manipulate specific signalling pathways in a transient manner and so influence the selection of specific pathways of differentiation by a stem cell. To explore this possibility we used RNAi to determine whether the transcription factor, OCT4, is required to maintain the undifferentiated state of hEC, as well as hES cells and whether forced knockdown of OCT4 expression results in differentiation towards trophectoderm. This opens up the possibility of targeting genes known to play a role in pluripotency or malignancy, using RNAi technologies, in cancer therapy.

siRNA mediated knockdown OF GFP, ¿2-microglobulin and OCT4

Details

Verlag LAP LAMBERT Academic Publishing
Ersterscheinung 29. Juli 2010
Maße 22 cm x 15 cm x 0.9 cm
Gewicht 233 Gramm
Format Softcover
ISBN-13 9783838379111
Seiten 144

Widerrufsantrag einreichen

Füllen Sie das folgende Formular aus, um Ihren Widerrufsantrag einzureichen.